Related Experiment Video

Updated: Jun 3, 2026

Practical Use of RNA Interference: Oral Delivery of Double-stranded RNA in Liposome Carriers for Cockroaches
08:26

Practical Use of RNA Interference: Oral Delivery of Double-stranded RNA in Liposome Carriers for Cockroaches

Published on: May 1, 2018

Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles

Mian M K Shahzad1, Lingegowda S Mangala, Hee Dong Han

  • 1Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Neoplasia (New York, N.Y.)
|April 8, 2011
PubMed

Insights

This study developed reconstituted high-density lipoprotein (rHDL) nanoparticles for delivering small interfering RNA (siRNA) to tumors. These novel nanoparticles effectively target cancer cells, offering a promising new strategy for cancer therapy.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Oncology

Background:

  • RNA interference (RNAi) shows therapeutic promise for cancers.
  • Efficient and biocompatible systemic delivery of small interfering RNA (siRNA) remains a challenge.
  • Tumor cells overexpress scavenger receptor type B1 (SR-B1) to uptake high-density lipoprotein (HDL).

Purpose of the Study:

  • To develop a novel siRNA delivery system using reconstituted HDL (rHDL) nanoparticles.
  • To exploit the SR-B1 receptor for targeted siRNA delivery to cancer cells.
  • To evaluate the therapeutic efficacy of rHDL-siRNA nanoparticles in preclinical cancer models.

Main Methods:

  • Formulation of siRNA-loaded reconstituted HDL (rHDL) nanoparticles.
  • In vivo systemic delivery assessment of rHDL nanoparticles.
  • Therapeutic evaluation in orthotopic mouse models of ovarian and colorectal cancer.
  • Silencing of signal transducer and activator of transcription 3 (STAT3) and focal adhesion kinase (FAK) expression.

Main Results:

  • rHDL nanoparticles demonstrated highly efficient in vivo systemic siRNA delivery mediated by SR-B1.
  • Targeted silencing of STAT3 and FAK was achieved in ovarian and colorectal cancer models.
  • Significant therapeutic effects were observed in preclinical cancer models.

Conclusions:

  • rHDL nanoparticles represent a novel and highly efficient carrier for siRNA delivery.
  • This technology holds potential for developing new cancer therapeutic strategies.
  • Targeted delivery via SR-B1 offers a promising approach for RNAi-based cancer treatment.

More Related Videos

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.